Abstract
Pulmonary aspergillosis remains a diagnostic and therapeutic challenge. Acute invasive aspergillosis (IPA) is increasingly seen in patients with respiratory diseases. Diagnosis is facilitated by the detection of mostly nodular infiltrates on high-resolution computed tomography and aspergillus galactomannan antigen testing of bronchoalveolar lavage fluid. A high grade of suspicion is needed to institute effective antimycotic treatment in time. Chronic pulmonary aspergillosis (CPA) is defined as progressive disease over a period of more than 3 months. The vast majority of CPA patients have underlying structural lung disease. Aspergillus-specific serum precipitins are frequently found. Antimycotic therapy is the mainstay of treatment, with a prolonged treatment duration.
Translated title of the contribution | Aspergillus infections |
---|---|
Original language | German |
Journal | Pneumologe |
Volume | 6 |
Issue number | 5 |
Pages (from-to) | 306-311 |
Number of pages | 6 |
ISSN | 1613-5636 |
DOIs | |
Publication status | Published - 2009 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)